The effective mechanism of action of aprecitentan (Tryvio), a new antihypertensive drug

Aprocitentan-Tryvio, a new antihypertensive drug that has attracted much attention in recent years, is regarded as another important breakthrough in the treatment of refractory hypertension. Compared with traditional antihypertensive drugs such as calcium channel blockers, diuretics, and beta-blockers, aprecitentan has a more precise target of action, mainly by blocking the endothelin (Endothelin) receptor signaling pathway, thereby effectively reducing the vasoconstrictive response. Endothelin is a type of potent vasoconstrictor peptide that is usually overactivated in patients with hypertension. Long-term effects can lead to increased vascular resistance and sustained increases in blood pressure. Aprecitentan blocks vasoconstriction signal transmission by selectively antagonizing receptors, helping blood vessels restore diastolic function, and ultimately achieves stable blood pressure reduction.

Compared with the first-generation endothelin receptor antagonists, aprecitentan has an optimized molecular structure, has higher selectivity and a longer half-life, allowing the drug to act on the vascular system for a longer period of time, reducing the number of daily doses and also reducing the risk of side effects caused by fluctuations in blood concentration. For patients with refractory hypertension, drugs with this type of innovative mechanism can provide additional means of blood pressure control when traditional drug regimens have limited effects, and can even achieve ideal blood pressure lowering effects in some people.

In addition, aprecitentan not only reduces blood pressure through a single vasodilation, but also shows potential clinical value in improving cardiovascular remodeling and reducing arterial stiffness. Some overseas studies have pointed out that this drug may have a positive impact on patients' heart and kidney function after long-term use, which is complementary to traditional antihypertensive drugs. It is worth noting that its research and development background emphasizes the pursuit of precision medicine, that is, more personalized treatment selection based on the pathophysiological characteristics of different patients.

Reference materials:https://go.drugbank.com/drugs/DB15059